LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

LLY

783.6

-1.64%↓

JNJ

152.55

-0.11%↓

ABBV

186.51

-1.24%↓

NVO

68.55

+1.24%↑

UNH

305.58

+0.32%↑

Search

REVOLUTION Medicines Inc

Abierto

SectorSanidad

37.77 0.85

Resumen

Variación precio

24h

Actual

Mínimo

36.91

Máximo

37.8

Métricas clave

By Trading Economics

Ingresos

-19M

-213M

BPA

-1.13

Margen de beneficios

-74.379

Empleados

616

EBITDA

-24M

-237M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+83.88% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-126M

7.5B

Apertura anterior

36.92

Cierre anterior

37.77

Noticias sobre sentimiento de mercado

By Acuity

69%

31%

347 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

REVOLUTION Medicines Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 jun 2025, 23:49 UTC

Ganancias

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 jun 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 jun 2025, 21:30 UTC

Ganancias

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Ganancias

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 jun 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 jun 2025, 23:39 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 jun 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 jun 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 jun 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 jun 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 jun 2025, 23:19 UTC

Adquisiciones, fusiones, absorciones

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 jun 2025, 22:06 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:15 UTC

Ganancias

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 jun 2025, 21:07 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 jun 2025, 21:06 UTC

Charlas de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 jun 2025, 20:52 UTC

Ganancias

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 jun 2025, 20:51 UTC

Ganancias

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

REVOLUTION Medicines Inc previsión

Precio Objetivo

By TipRanks

83.88% repunte

Estimación a 12 Meses

Media 70.63 USD  83.88%

Máximo 80 USD

Mínimo 57 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REVOLUTION Medicines Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

10

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

40.67 / 41.96Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

347 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.